scholarly journals S6. Association between the progesterone receptor and HER-2/neu in oestrogen receptor-positive breast cancer

2004 ◽  
Vol 2 (9) ◽  
pp. 93
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Oestrogen Receptor ◽  
Her 2 ◽  
Positive Breast Cancer

scholarly journals Estrogen Receptor-negative/progesterone Receptor-positive and Her-2 Negative Breast Cancer Might No Longer Be Classified as Hormone Receptor Positive Breast Cancer

2020 ◽  
Author(s):  
Hongjuan Zheng ◽  
Chenyang Ge ◽  
Haiping Lin ◽  
Lunpo Wu ◽  
Qinghua Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Endocrine Therapy ◽  
Treatment Strategies ◽  
Biological Entity ◽  
Cancer Specific Survival ◽  
Her 2 ◽  
Positive Breast Cancer

Abstract Background: The estrogen receptor (ER)-negative/progesterone receptor (PR)-positive (sPR positive) phenotype is an infrequent and independent biological entity. However, the prognosis of patients with sPR positive and her-2 negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them.Methods: Patients during 2010–2014 were identified from Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to evaluate cancer-specific survival (CSS). The propensity score matching (PSM) method was used to balance differences of characteristics in groups. The Life-Table method was used to calculate 5-year CSS rates and the annual hazard rate of death (HRD). Results: A total of 97,527 patients were included, and only 745 (0.76%) patients were sPR positive phenotype. The majority of sPR positive breast cancer were basal-like subtype. Survival analysis showed that the sPR positive breast cancer had similar prognosis comparing to ER-negative/PR-negative (dHR negative) breast cancer, and had the highest HRD during the initial 1-2 years of follow-up, then maintained the HRD of almost zero during the late years of follow-up. Conclusions: The patients with sPR positive and her-2 negative breast cancer, similar to dHR negative breast cancer, had a worse survival, and could benefit from chemotherapy significantly. However, the escalating endocrine therapy was not recommended for sPR positive patients. The patients with sPR positive should be excluded from future clinical trials concerning endocrine therapy.

Progesterone Receptor in Estrogen Receptor–Positive Breast Cancer: The Association Between HER-2 and Lymph Node Involvement Is Age Related

2006 ◽  
Vol 24 (16) ◽  
pp. 2595-2595 ◽  
Author(s):  
Patrick Neven ◽  
Nathalie Pochet ◽  
Maria Drijkoningen ◽  
Frederic Amant ◽  
Frank De Smet ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Lymph Node ◽  
Progesterone Receptor ◽  
Lymph Node Involvement ◽  
Age Related ◽  
Estrogen Receptor Positive ◽  
Node Involvement ◽  
Her 2 ◽  
Positive Breast Cancer

scholarly journals Estrogen receptor-negative/progesterone receptor-positive and her-2 negative breast cancer might no longer be classified as hormone receptor positive breast cancer

2020 ◽  
Author(s):  
Hongjuan Zheng ◽  
Chenyang Ge ◽  
Haiping Lin ◽  
Lunpo Wu ◽  
Qinghua Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Endocrine Therapy ◽  
Treatment Strategies ◽  
Biological Entity ◽  
Cancer Specific Survival ◽  
Her 2 ◽  
Positive Breast Cancer

Background: The estrogen receptor (ER)-negative/progesterone receptor (PR)-positive (sPR positive) phenotype is an infrequent and independent biological entity. However, the prognosis of patients with sPR positive and her-2 negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them. Methods: Patients during 2010–2014 were identified from Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to evaluate cancer-specific survival (CSS). The propensity score matching (PSM) method was used to balance differences of characteristics in groups. The Life-Table method was used to calculate 5-year CSS rates and the annual hazard rate of death (HRD). Results: A total of 97,527 patients were included, and only 745 (0.76%) patients were sPR positive phenotype. The majority of sPR positive breast cancer were basal-like subtype. Survival analysis showed that the sPR positive breast cancer had similar prognosis comparing to ER-negative/PR-negative (dHR negative) breast cancer, and had the highest HRD during the initial 1-2 years of follow-up, then maintained the HRD of almost zero during the late years of follow-up. Conclusions: The patients with sPR positive and her-2 negative breast cancer, similar to dHR negative breast cancer, had a worse survival, and could benefit from chemotherapy significantly. However, the escalating endocrine therapy was not recommended for sPR positive patients. The patients with sPR positive should be excluded from future clinical trials concerning endocrine therapy.

Sign in / Sign up

Export Citation Format

Share Document